Dexcom Inc Stock Today
| DXCM Stock | USD 68.47 0.08 0.12% |
Performance0 of 100
| Odds Of DistressLess than 9
|
DexCom is selling at 68.47 as of the 12th of September 2024; that is 0.12 percent decrease since the beginning of the trading day. The stock's lowest day price was 66.86. DexCom has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Note, on April 16, 2020, Senator Tina Smith of US Senate acquired $250k to $500k worth of DexCom Inc's common stock.
Business Domain Health Care Equipment & Services | IPO Date 14th of April 2005 | Category Healthcare | Classification Health Care |
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the United States and internationally. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California. The company has 400.73 M outstanding shares of which 7.56 M shares are currently shorted by private and institutional investors with about 0.88 trading days to cover. More on DexCom Inc
Moving together with DexCom Stock
| 0.79 | DH | Definitive Healthcare | PairCorr |
| 0.89 | ELAB | Elevai Labs, Common | PairCorr |
| 0.64 | XAIR | Beyond Air | PairCorr |
Moving against DexCom Stock
DexCom Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO and President and Director | Kevin Sayer | ||||
| Thematic Idea | Medical Equipment (View all Themes) | ||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, SP 500 Index, Nasdaq 100, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Medical Equipment, Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare (View all Sectors) | ||||
| Excise Tax Activities | Animal Testing | ||||
| Average Analyst Recommendation | |||||
Debt LevelsDexCom can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand DexCom's financial leverage. It provides some insight into what part of DexCom's total assets is financed by creditors.
| |||||
DexCom Inc (DXCM) is traded on NASDAQ Exchange in USA. It is located in 6340 Sequence Drive, San Diego, CA, United States, 92121 and employs 9,500 people. DexCom is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 27.47 B. DexCom Inc conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 400.73 M outstanding shares of which 7.56 M shares are currently shorted by private and institutional investors with about 0.88 trading days to cover.
DexCom Inc currently holds about 2.37 B in cash with 748.5 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.14.
Check DexCom Probability Of Bankruptcy
Ownership AllocationDexCom holds a total of 400.73 Million outstanding shares. The majority of DexCom Inc outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in DexCom Inc to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in DexCom. Please pay attention to any change in the institutional holdings of DexCom Inc as this could imply that something significant has changed or is about to change at the company. Please note that on April 16, 2020, Senator Tina Smith of US Senate acquired $250k to $500k worth of DexCom Inc's common stock.
Check DexCom Ownership Details
DexCom Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Ubs Asset Mgmt Americas Inc | 2024-06-30 | 6.3 M | |
| Amvescap Plc. | 2024-06-30 | 6.2 M | |
| Jpmorgan Chase & Co | 2024-03-31 | 5.7 M | |
| Artisan Partners Limited Partnership | 2024-06-30 | 5.6 M | |
| American Century Companies Inc | 2024-06-30 | 5.5 M | |
| Norges Bank | 2024-06-30 | 5.4 M | |
| Wellington Management Company Llp | 2024-06-30 | 5.3 M | |
| Morgan Stanley - Brokerage Accounts | 2024-03-31 | 5 M | |
| Blair William & Co | 2024-03-31 | 4.5 M | |
| Vanguard Group Inc | 2024-06-30 | 46.5 M | |
| Blackrock Inc | 2024-06-30 | 34.5 M |
DexCom Historical Income Statement
DexCom Stock Against Markets
DexCom Corporate Management
| Shelly Selvaraj | Senior Officer | Profile | |
| Leverne Marsh | Executive Marketing | Profile | |
| Matthew Dolan | Corporate Strategy | Profile | |
| Teri Lawver | Executive Officer | Profile | |
| Jereme Sylvain | CFO VP | Profile | |
| Paul Flynn | Ex Revenue | Profile |
Additional Information and Resources on Investing in DexCom Stock
When determining whether DexCom Inc is a strong investment it is important to analyze DexCom's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact DexCom's future performance. For an informed investment choice regarding DexCom Stock, refer to the following important reports:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DexCom Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DexCom. If investors know DexCom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DexCom listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.266 | Earnings Share 1.61 | Revenue Per Share 10.088 | Quarterly Revenue Growth 0.153 | Return On Assets 0.0626 |
The market value of DexCom Inc is measured differently than its book value, which is the value of DexCom that is recorded on the company's balance sheet. Investors also form their own opinion of DexCom's value that differs from its market value or its book value, called intrinsic value, which is DexCom's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DexCom's market value can be influenced by many factors that don't directly affect DexCom's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DexCom's value and its price as these two are different measures arrived at by different means. Investors typically determine if DexCom is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DexCom's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.